Protagonist Therapeutics, Inc

For the period ended Sep 30, 2026. Filed Nov 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 6, 2026

PTGX$135.90+2.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)


· · September 30, · · December 31,
· · 2026 · · 2025
Assets
Current assets:
Cash and cash equivalents	$498,298	$128,390
Marketable securities	301,766	438,974
Receivable from collaboration partner	283,785	121
Contract asset	4,007	—
Prepaid expenses and other current assets	13,203	10,089
Total current assets	1,101,059	577,574
Marketable securities - noncurrent	34,557	78,638
Property and equipment, net	3,321	3,860
Restricted cash - noncurrent	287	287
Operating lease right-of-use asset	6,495	7,829
Other non-current asset	832	—
Total assets	$1,146,551	$668,188
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$5,921	$5,339
Accrued expenses and other payables	26,560	28,269
Deferred revenue	16,311	9,550
Income taxes payable	4,218	—
Operating lease liability	2,454	2,283
Total current liabilities	55,464	45,441
Operating lease liability - noncurrent	6,177	8,040
Total liabilities	61,641	53,481
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding	—	—
Common stock, $0.00001 par value, 180,000,000 shares authorized; 65,256,152 and 62,577,897 shares issued as of September 30, 2026 and December 31, 2025, respectively, and 65,215,592 and 62,577,897 shares outstanding as of September 30, 2026 and December 31, 2025, respectively	1	1
Additional paid-in capital	1,176,019	1,084,736
Treasury stock	(5,791)	—
Accumulated other comprehensive (loss) income	(1,295)	641
Accumulated deficit	(84,024)	(470,671)
Total stockholders’ equity	1,084,910	614,707
Total liabilities and stockholders’ equity	$1,146,551	$668,188

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.